Silencing of FGF-21 expression promotes hepatic gluconeogenesis and glycogenolysis by regulation of the STAT3-SOCS3 signal

FEBS Journal

Volumn 281, Issue 9, 2014, Pages 2136-2147

  Wang, Cong ^a   Dai, Jihuan ^a   Yang, Mengliu ^a   Deng, Guangjiang ^a   Xu, Shengnan ^a   Jia, Yanjun ^a   Boden, Guenther ^b   Ma, Zhongmin A ^c   Yang, Gangyi ^a   Li, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

FGF 21 knockdown; insulin resistance; liver glucose fluxes; SOCS3; STAT3

Indexed keywords

FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SHORT HAIRPIN RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVATION; FATTY ACID BLOOD LEVEL; GENE SILENCING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCOGENOLYSIS; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOVIRIDAE; MUS;

FGF-21 KNOCKDOWN; INSULIN RESISTANCE; LIVER GLUCOSE FLUXES; SOCS3; STAT3;

ANIMALS; FIBROBLAST GROWTH FACTORS; GENE SILENCING; GLUCONEOGENESIS; GLYCOGENOLYSIS; HOMEOSTASIS; INSULIN RESISTANCE; LIVER; MICE; MICE, KNOCKOUT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84899919611     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12767     Document Type: Article

References (40)

1. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H & Boden G (2007) Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 115, 1-4.
2. Li L, Yang G, Ning H, Yang M, Liu H & Chen W (2008) Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 82, 209-213.
3. Li K, Li L, Yang M, Zong H, Liu H & Yang G (2009) Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 161, 391-395.
4. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP & Wong KK (2008) Adipose fibroblast growth factor 21 is upregulated by peroxisome proliferator-activated receptor c and altered metabolic states. Mol Pharmacol 74, 403-412.
5. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246-1253.
6. Fisher MF, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS & Maratos- Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)- resistant state. Diabetes 59, 2781-2789.
7. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115, 1627-1635.
8. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE & Kharitonenkov A (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027.
9. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259.
10. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB & Etgen GJ (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774-781.
11. Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, Zhang D, Kahn M, Samuel VT, Jurczak MJ, et al. (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154, 3099-3109.
12. Gable D, Sanderson SC & Humphries SE (2007) Genotypes, obesity and type 2 diabetes - can genetic information motivate weight loss? A review. Clin Chem Lab Med 45, 301-308.
13. Hansmann G, Wagner RA, Schellong S, Perez VA & Urashima T (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-c activation. Circulation 115, 1275-1284.
14. To AW, Ribe EM, Chuang TT, Schroeder JE & Lovestone S (2011) The e3 and e4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone-treated mice. PLoS ONE 6, e16991.
15. Li L, Miao Z, Liu R, Yang M, Liu H & Yang G (2011) Liraglutide prevents hypoadiponectinemiainduced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 17, 1168-1178.
16. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T & Kobayashi M (2007) Effects of pioglitazone on suppressor of cytokine signaling 3 expression. Diabetes 56, 795-803.
17. Ramadoss P, Unger-Smith NE, Lam FS & Hollenberg AN (2009) STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol Endocrinol 23, 827-837.
18. Ling L, Gangyi Y, Shaochuan S, Mengliu Y, Hua L & Boden G (2012) The effects of fibroblast growth factor- 21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol 348, 21-26.
19. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, Hashimoto N, Kido Y, Mori T, Sakaue H, et al. (2004) Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10, 168-174.
20. Howard JK, Flier JS, Howard JK & Flier JS (2006) Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17, 365-371.
21. Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821-827.
22. Breslow JL (1996) Mouse models of atherosclerosis. Science 272, 685-688.
23. Zhang SH, Reddick RL, Piedrahita JA & Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468-471.
24. Chen Y, Yang G, Li L, Li K & Chen W (2009) The changes of glucose-lipid metabolism in ApoE-/-mice with high-fat induced insulin resistance. Chin J Diabetes 17, 590-592.
25. Utter MF & Keech DB (1963) Pyruvate carboxylase. I. Nature of the reaction. J Biol Chem 238, 2603-2608.
26. Ballard FJ & Hanson RW (1967) The citrate cleavage pathway and lipogenesis in rat adipose tissue: replenishment of oxaloacetate. J Lipid Res 8, 73-79.
27. Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, Teshigawara K, Matsuki Y, Watanabe E, Hiramatsu R, et al. (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 8, 3267-3275.
28. Uno T, He T, Usui I, Kanatani Y, Bukhari A, Fujisaka S, Yamazaki Y, Suzuki H, Iwata M, Ishiki M, et al. (2008) Long-term interleukin-1a treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes. Horm Metab Res 40, 8-12.
29. Run-Zhe S, Feng Z, Fang W, De-Chun F, Xi-Hua L, Wei-Hua R, Xiao-Lin W, Xue Y, Xiao-Dong L, Lei H, et al. (2009) Adiponectin deficiency impairs liver regeneration through attenuating STAT3 phosphorylation in mice. Lab Invest 89, 1043-1052.
30. Ueki K, Kondo T, Tseng YH & Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 10, 10422-10427.
31. Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka T, Mori H, Iida M & Yoshimura A (2007) The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12, 143-154.
32. Shi H, Cave B, Inouye K, Bjorbaek C & Flier JS (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55, 699-707.
33. Yang M, Zhang L, Wang C, Liu H, Boden G, Yang G & Li L (2012) Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS ONE 7, e48392.
34. Sun B, Yang G, Yang M, Liu H, Boden G & Li L (2012) Long-term high-fat diet links the regulation of the insulin-sensitizing fibroblast growth factor-21 and visfatin. Cytokine 59, 131-137.
35. Muse ED, Lam TK, Scherer PE & Rossetti L (2007) Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest 117, 1670-1678.
36. Ling L, Gangyi Y, Shaochuan S, Mengliu Y, Hua L & Boden G (2009) The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-a (TNF-a) in vivo. Cytokine 45, 12-19.
37. Qin S, Ling L, Renzhe L, Mengliu Y, Hua L & Gangyi Y (2009) Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Ann Med 41, 311-320.
38. Zhang L, Yang M, Ren H, Hu H, Boden G, Li L & Yang G (2013) GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int 33, 794-804.
39. Ramesha CS, Paul R & Ganguly J (1980) Effect of dietary unsaturated oils on the biosynthesis of cholesterol, and on biliary and fecal excretion of cholesterol and bile acids in rats. J Nutr 110, 2149-2158.
40. Ferre T, Riu E, Bosch F & Valera A (1996) Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 10, 1213-1218.